Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Gist2011

1,160 views

Published on

  • Be the first to comment

  • Be the first to like this

Gist2011

  1. 1. <ul><li>62yr old male pt with pmh of HTN, ESRD, with severe headache , chest pain and nausea since last 3 days </li></ul><ul><li>Pt was medically stabilized transferred to medicine floor for further management </li></ul><ul><li>Hgb between 7-9 and FOBT was positive </li></ul>
  2. 2. <ul><li>-GI consulted , recommended endoscopy </li></ul><ul><li>- Endoscopy revealed 3cm sub mucosal mass in proximal body stomach </li></ul><ul><li>Multiple biopsies were taken </li></ul>
  3. 3. <ul><li>Spindle cells from biopsy specimen were positive for CD117 and CD 34 </li></ul>
  4. 5. Epidemiology <ul><li>The most common nonepithelial benign neoplasm involving the GI tract </li></ul><ul><li>the annual incidence of GIST in the United States is at least 4000 to 6000 new cases </li></ul><ul><li>  Although the majority of GISTs appear to be sporadic, several kindreds with heritable mutations in the KIT gene have been identified. </li></ul>
  5. 6. MOLECULAR PATHOLOGY <ul><li>They are characterized by expression of a tyrosine kinase growth factor receptor, also called kit receptor or CD117. </li></ul><ul><li>This expression allows unchecked growth of tumor and resistance to apoptosis. </li></ul><ul><li>KIT gene mutations is present in exon 9, 13, or 17, that results in uncontrolled KIT signaling </li></ul>
  6. 7. - These tumors differ immunohistologically and behaviorally from other mesenchymal tumors such as leiomyosarcomas, which do not express kit antigen
  7. 8. Cellular origin of GISTs <ul><li>Interstitial cells of Cajal (ICC) </li></ul><ul><li>GI pacemaker cells </li></ul><ul><li>form the interface between the autonomic innervation of the bowel wall and the smooth muscle itself </li></ul><ul><li>immunophenotypic and ultrastructural features of both smooth muscle and neuronal differentiation and serve to regulate peristalsis </li></ul>
  8. 9. Histopathology <ul><li>Spindle cell type — 70 percent </li></ul><ul><li>Epithelioid type — 20 percent </li></ul><ul><li>Mixed type — 10 percent </li></ul>
  9. 10. <ul><li>(upper panel) is composed of spindle cells with elongated nuclei and eosinophilic cytoplasm </li></ul><ul><li>(lower panel) consist of epithelioid cells having round central nuclei within eosinophilic or clear cytoplasm. </li></ul>
  10. 11. TNM staging Primary tumor (T) TX Primary tumor cannot be assessed T0 No evidence for primary tumor T1 Tumor 2 cm or less T2 Tumor more than 2 cm but not more than 5 cm T3 Tumor more than 5 cm but not more than 10 cm T4 Tumor more than 10 cm in greatest dimension Regional lymph nodes (N) N0 No regional lymph node metastasis* N1 Regional lymph node metastasis Distant metastasis (M) M0 No distant metastasis M1 Distant metastasis
  11. 12. <ul><li>Features favoring benign lesions in general like: </li></ul><ul><ul><li>Size less than 5 cm </li></ul></ul><ul><ul><li>Low number of mitosis per HPF </li></ul></ul><ul><ul><li>No mucosal invasion </li></ul></ul><ul><ul><li>Low cellularity </li></ul></ul><ul><ul><li>Low markers of cell proliferation </li></ul></ul><ul><li>The above have shown to be associated with malignant behavior in some but not in other studies. </li></ul><ul><li>With prolonged follow up any GIST has the potential to behave in a malignant fashion. </li></ul><ul><li>50% of primary localized tumors that are resected relapse after 5 years of follow up </li></ul>
  12. 13. CLINICAL MANIFESTATIONS  <ul><li>Overt GI bleeding — 40 percent </li></ul><ul><li>Abdominal mass — 40 percent </li></ul><ul><li>Abdominal pain — 20 percent </li></ul><ul><li>GISTs frequently metastasize to liver and peritoneum and rarely to regional lymph nodes. </li></ul>
  13. 14. DIAGNOSTIC WORK-UP  <ul><li>CT scan : to characterize an abdominal mass, evaluate its extent, and the presence or absence of metastatic disease. </li></ul><ul><li>The usual CT appearance of a GIST is that of a solid smoothly contoured mass that enhances brightly with IV contrast. </li></ul>
  14. 15. Tumor arising from gastric wall
  15. 16. Upper endoscopy  <ul><li>Endoscopy may be useful to further characterize the lesion if a gastric mass is identified </li></ul><ul><li>Endoscopic biopsies using standard techniques usually do not obtain sufficient tissue for a definite diagnosis </li></ul>
  16. 17. Endoscopic view of an actively oozing 20mm by 30mm submucosal mass in the body of the stomach body (left panel). Bleeding was controlled by injection of a 1:10,000 epiniphrine solution and bioploar electrocautery (right panel).
  17. 18. Endoscopic ultrasonography  <ul><li>EUS-guided fine-needle aspiration — for cytologic analysis, immunohistochemistry, and KIT mutations </li></ul><ul><li>If metastatic disease is suspected or if preoperative imatinib is considered prior to attempted resection </li></ul>
  18. 19. First patient to be treated with Imatinib <ul><li>54 year old female with metastatic GIST diagnosed in 1996 </li></ul><ul><li>Liver metastases and multiple small intra-abdominal metastases were excised in February 1998 and in September 1998 </li></ul><ul><li>Seven cycles of chemotherapy with doxorubicin, </li></ul><ul><li>ifosfamide, and dacarbazine with no response </li></ul>
  19. 20. <ul><li>In March 1999 had bowel obstruction and on laparotomy had diffuse intraabdominal mets. </li></ul><ul><li>Received thalidomide and interferon with no response </li></ul><ul><li>Treatment with 400 mg Imatinib once daily was started in March 2000. </li></ul>
  20. 22. Before and after im
  21. 23. IMATINIB FOR GIST <ul><li>Imatinib is approved in the United States for use as adjuvant therapy for any primary GIST ≥3 cm. </li></ul><ul><li>tyrosine kinase inhibitors such as imatinib block signaling via KIT and PDGFRA, thus halting tumor proliferation. </li></ul><ul><li>median survival of patients with advanced GIST increased from an average of 18 to 57 months in the trial with the longest follow-up to date </li></ul>
  22. 24.   Assessing response <ul><li>PET scanning : responses can be observed within 24 hours of starting therapy. </li></ul><ul><li>Rarely used to assess the response of therapy </li></ul><ul><li>Can be used for a patient with a borderline resectable GIST or a potentially resectable tumor that requires extensive organ disruption who is being treated with initial imatinib </li></ul>
  23. 25. contd….. <ul><li>CT scan: re-evaluation should be done two to three months after starting therapy </li></ul>
  24. 26. Side effects: <ul><li>fluid retention: diuretics useless, upright during day </li></ul><ul><li>diarrhea: loperamide, atropine </li></ul><ul><li>nausea:antacid, proton pump inhibitor </li></ul><ul><li>muscle cramps: Ca or Mg supplements </li></ul><ul><li>Rash: resolves with continued treatment </li></ul>
  25. 27. MANAGEMENT OF REFRACTORY OR INTOLERANT PATIENTS <ul><li>Switching to an alternative TKI, sunitinib </li></ul><ul><li>Dose escalation may be considered in patients started on imatinib 400 mg daily who, after careful review of radiologic studies, are judged to have clear evidence of disease progression. </li></ul>
  26. 28. GENERAL SURGICAL PRINCIPLES  <ul><li>Preoperative biopsy:biopsy is preferred to confirm the diagnosis if metastatic disease is suspected or if preoperative imatinib is considered prior to attempted resection in a patient who has a large locally advanced lesion thought to represent a GIST. </li></ul><ul><li>All GISTs ≥2 cm in size should be resected. </li></ul>
  27. 29. <ul><li>The natural history of these and other GISTs between 1 and 2 cm, including their growth rate and metastatic potential, remains unknown. </li></ul><ul><li>initial therapy with imatinib may be preferred if a tumor is borderline resectable, or if resection would necessitate extensive organ disruption. </li></ul>
  28. 30. Management of gastrointestinal stromal cell tumors
  29. 31. POSTTREATMENT FOLLOW-UP <ul><li>completely resected GIST tumor: every three to six months for five years, then annually. </li></ul><ul><li>locally advanced or metastatic disease who are receiving imatinib: every three to six months. </li></ul>
  30. 32. Further reading <ul><li>Abeloff: Abeloff's Clinical Oncology, 4th ed. </li></ul><ul><li>Feldman: Sleisenger & Fordtran's Gastrointestinal and Liver Disease, 9th ed. </li></ul><ul><li>Quek R - Hematol Oncol Clin North Am - 01-FEB-2009; 23(1): 69-78, viii </li></ul>

×